Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Heinemann, Lucy ^a   Simpson, Guy R ^a   Boxall, Angela ^a   Kottke, Timothy ^b   Relph, Kate L ^a   Vile, Richard ^b   Melcher, Alan ^c   Prestwich, Robin ^c   Harrington, Kevin J ^d   Morgan, Richard ^a   Pandha, Hardev S ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b MAYO CLINIC   (United States)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; IODIDE; LIPOCORTIN 5; ONCOLYTIC VIRUS; PACLITAXEL; PROPIDIUM IODIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL DEATH; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAMMALIAN ORTHOREOVIRUS; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROSTATE CANCER; REOVIRUS INFECTION; VIRUS REPLICATION; WESTERN BLOTTING; ACETYLATION; ANIMAL; APOPTOSIS; DRUG SCREENING; METABOLISM; MICROTUBULE; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PROSTATE TUMOR; REOVIRUS; TUMOR CELL LINE; TUMOR VOLUME; ULTRAVIOLET RADIATION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG SYNERGISM; HUMANS; MALE; MICE; MICROTUBULES; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; REOVIRIDAE; TAXOIDS; TUMOR BURDEN; ULTRAVIOLET RAYS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79957895031     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-221     Document Type: Article

References (42)

1. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977, 54:307-15. 10.1007/BF01314776, 562142.
2. Duncan MR, Stanish SM, Cox DC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 1978, 28:444-9. 354293, 214572.
3. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998, 282:1332-4.
4. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998, 17:3351-62. 10.1093/emboj/17.12.3351, 1170673, 9628872.
5. Strong JE, Lee PW. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 1996, 70:612-6. 189854, 8523580.
6. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003, 63:348-53.
7. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22. 10.1038/nrc969, 12509763.
8. Forsyth P, Roldan G, George D, Wallace C, Palmer CA, Morris D, et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008, 16:627-32. 10.1038/sj.mt.6300403, 18253152.
9. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008, 14:7127-37. 10.1158/1078-0432.CCR-08-0524, 18981012.
10. Rowan S, Rachet B, Alexe DM, Cooper N, Coleman MP. Survival from prostate cancer in England and Wales up to 2001. Br J Cancer 2008, 99(Suppl 1):S75-7. 2557548, 18813268.
11. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-20. 10.1056/NEJMoa041318, 15470214.
12. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-12. 10.1056/NEJMoa040720, 15470213.
13. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991, 34:992-8. 10.1021/jm00107a017, 1672159.
14. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993, 32:2747-55. 10.1021/bi00062a003, 8096151.
15. Eisenhauer EA, Vermorken JB, . The taxoids Comparative clinical pharmacology and therapeutic potential. Drugs 1998, 55:5-30. 10.2165/00003495-199855010-00002, 9463787, The taxoids.
16. Babiss LE, Luftig RB, Weatherbee JA, Weihing RR, Ray UR, Fields BN. Reovirus serotypes 1 and 3 differ in their in vitro association with microtubules. J Virol 1979, 30:863-74. 353397, 480468.
17. Kim J, Parker JS, Murray KE, Nibert ML. Nucleoside and RNA triphosphatase activities of orthoreovirus transcriptase cofactor mu2. J Biol Chem 2004, 279:4394-403.
18. Kobayashi T, Ooms LS, Chappell JD, Dermody TS. Identification of functional domains in reovirus replication proteins muNS and mu2. J Virol 2009, 83:2892-906. 10.1128/JVI.01495-08, 2655549, 19176625.
19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
20. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008, 9:533-42. 10.1016/S1470-2045(08)70107-4, 18495536.
21. Chang J, Zhao X, Wu X, Guo Y, Guo H, Cao J, et al. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol Ther 2009, 8:676-82. 10.4161/cbt.8.8.7913, 19242097.
22. Rusan NM, Fagerstrom CJ, Yvon AM, Wadsworth P. Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein-alpha tubulin. Mol Biol Cell 2001, 12:971-80. 32280, 11294900.
23. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 1995, 4:253-65. (2004).
24. McCrae MA, Joklik WK. The nature of the polypeptide encoded by each of the 10 double-stranded RNA segments of reovirus type 3. Virology 1978, 89:578-93. 10.1016/0042-6822(78)90199-X, 716218.
25. Mustoe TA, Ramig RF, Sharpe AH, Fields BN. Genetics of reovirus: identification of the ds RNA segments encoding the polypeptides of the mu and sigma size classes. Virology 1978, 89:594-604. 10.1016/0042-6822(78)90200-3, 716219.
26. Brentano L, Noah DL, Brown EG, Sherry B. The reovirus protein mu2, encoded by the M1 gene, is an RNA-binding protein. J Virol 1998, 2:8354-7. 7.
27. Coombs KM. Temperature-sensitive mutants of reovirus. Curr Top Microbiol Immunol 1998, 233:69-107.
28. Parker JS, Broering TJ, Kim J, Higgins DE, Nibert ML. Reovirus core protein mu2 determines the filamentous morphology of viral inclusion bodies by interacting with and stabilizing microtubules. J Virol 2002, 76:4483-96. 10.1128/JVI.76.9.4483-4496.2002, 155082, 11932414.
29. Yin P, Keirstead ND, Broering TJ, Arnold MM, Parker JS, Nibert ML, et al. Comparisons of the M1 genome segments and encoded mu2 proteins of different reovirus isolates. Virol J 2004, 1:6. 10.1186/1743-422X-1-6, 524354, 15507160.
30. Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, et al. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 2009, 8:47. 10.1186/1476-4598-8-47, 2723073, 19594950.
31. Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther 2009, 16(7):551-60. 10.1038/cgt.2009.10, 2843507, 19197321.
32. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000, 6:879-85. 10.1038/78638, 10932224.
33. Cheong SC, Wang Y, Meng JH, Hill R, Sweeney K, Kirn D, et al. E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther 2008, 15:40-50. 10.1038/sj.cgt.7701099, 2268748, 18034197.
34. Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, et al. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res 2009, 15:511-9. 10.1158/1078-0432.CCR-08-1088, 19147756.
35. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999, 1:162. 10.1038/sj.neo.7900016, 1508135, 10933051.
36. Post DE, Fulci G, Chiocca EA, Van Meir EG. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther 2004, 4:41-51. 10.2174/1566523044577988, 15032613.
37. Eisenberg DP, Adusumilli PS, Hendershott KJ, Yu Z, Mullerad M, Chan MK, et al. 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg 2005, 9:1068-77. discussion 1077-9, 10.1016/j.gassur.2005.06.024, 1373688, 16269377.
38. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 1999, 10:3013-29. 10.1089/10430349950016410, 10609661.
39. Petrowsky H, Roberts GD, Kooby DA, Burt BM, Bennett JJ, Delman KA, et al. Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol 2001, 75:7050-8. 10.1128/JVI.75.15.7050-7058.2001, 114433, 11435585.
40. Adusumilli PS, Chan MK, Chun YS, Hezel M, Chou TC, Rusch VW, et al. Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther 2006, 5:48-53. 10.4161/cbt.5.1.2237, 1383726, 16294031.
41. Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS. REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. Clin Cancer Res 2010, 15;16(22):5564-5572.
42. Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, Coffey M, Harrington KJ, Morgan R. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 2009, 15(19):6158-66. 10.1158/1078-0432.CCR-09-0796, 19773377.